Valby, 25 June 2018 Lu AF28996 is the third compound added to Lundbeck's clinical development pipeline in 2018. H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a potential new treatment of Parkinson's disease.

New clinical phase III data from a study conducted in Japan demonstrate the efficacy of vortioxetine compared to placebo for the treatment of Major Depressive Disorder (MDD) in Japanese adults Positive results suggest that vortioxetine may be a potential treatment option for Japanese patients with